In a recent study we could show that neopterin inhibits nitric oxide-induced apoptosis in ovarian carcinoma cells. This may provide an explanation for the correlation between increased levels of neopterin derivatives and the unfavorable prognosis in patients with ovarian cancer that has been described in the literature. To obtain additional information on the mode of action of neopterin derivatives within the tumor environment, we studied the effects of neopterin (100 and 1000 μΜ) and 7,8-dihydroneopterin (100, 500, and 1000 μΜ) on mitochondrial dehydrogenase activity in three different ovarian carcinoma cell lines (2774, HOC-1, and OVCAR-3). 7,8-dihydroneopterin was an effective stimulus of mitochondrial enzyme turnover rate in any cell culture model under investigation. This suggests that the pteridine compound stabilizes tumor cell viability and therefore acts as a promotor of tumor growth. In contrast to 7.8-dihydroneopterin, neopterin did not affect mitochondrial dehydrogenases in 2774, HOC-7, or OVCAR-3 cells. However, in HOC-7 and OCVAR-3, neopterin was found to antagonize the stimulating effects of 7,8-dihydroneopterin. This might be due to the different impact of both pteridine compounds on the redox status in these cells. Our new data provide further evidence of distinct biochemical effects of neopterin derivatives in ovarian carcinoma cells. Neopterin and 7,8-dihydroneopterin may be involved in separate stages of cellular changes that lead to malignancy or promote tumor progression.
Introduction
Increased levels of neopterin derivatives have been reported in various forms of cancer including ovarian carcinomas, and a significant correlation between increased neopterin concentrations and progression as well as outcome of the disease were shown (1-3). Previous investigations have supported the concept that neopterin derivatives itself exhibit a number of biochemical functions via interactions with the cellular redox state, thereby representing endogenous mediators of the cellular immune system that might affect other agonists and target cells in the course of an inflammatory response (4) . In addition, the direct actions of pteridine compounds may provide an explanation for the observed correlation between high levels of neopterin derivatives and unfavorable cancer prognosis. In previous studies by our group, nitric oxide production in ovarian carcinoma cell lines was found to be associated with apoptotic cell death, i.e. iNOS gene expression induced by pro-inflammatory cytokines corresponded to the degree of apoptosis in these cells (5, 6) . In a follow-up study, we could show that neopterin inhibited the cytokine-induced NO synthesis in these cells (7) . Thus, neopterin may inhibit apoptosis in ovarian carcinoma cells susceptible to NO and there is reason to speculate that neopterin influences tumor cell growth and proliferation. Angiogenesis is an essential prerequisite for the delivery of nutrients and oxygen to the developing tumor tissue. Among the growth factors implicated in the onset of angiogenesis in ovarian tumor tissue, vascular endothelial growth (8) . HIF-1 is known to be a key regulator for both VEGF and EPO gene expression. In contrast to these data, neopterin was found to suppress hypoxia-induced EPO synthesis in a hepatocellular carcinoma cell line (9) . Assuming that neopterin is a promoter of tumor cell growth, this sounds paradoxical, since one would expect a benefit from the inhibition of a pro-angiogenic factor. Heterogeneities between tumour cells of different tissues of origin may account for the discrepancies between these observations and further studies are necessary to establish the role of neopterin derivatives in tumor progression. In the present study, we investigated the potential of neopterin and 7,8-dihydroneopterin (DHN) on the metabolic activity of three different ovarian carcinoma cell lines.
Material and Methods

Cell culture
The human ovarian carcinoma cell lines OVCAR-3, HOC-7, and 2774 were kindly provided by Dr. C. Dittrich, University of Vienna, and Dr. L. Old, Memorial Sloan Kettering Center, New York, and cultured under standard conditions in 25 cm 2 culture flasks (Nunc, Roskilde, Denmark) in Dulbecco's modified minimum essential medium (DMEM) with the addition of 10% fetal calf serum (FCS), 1 % nonessential amino acids, 2 raM L-glutamine, 100 U/ml penicillin, and 100 μ §/ιη1 streptomycin. For experiments, cells were seeded in 96-well tissue culture plates (Nunc, Roskilde, Denmark) at a density of 1 χ 10 3 cells/cm 2 and allowed to attach for 48 h. Semi-confluent cells were growth arrested in serum-deprived DMEM 24 h prior to incubation. Culture medium including 10% FCS was renewed and neopterin derivatives were added for a 24 h incubation period, respectively. Both neopterin and DHN were prepared as stock solutions (1 mM) in DMEM immediately before the experiments. Neopterin was dissolved by sonication in a water bath at 37°C for 10 min.
Determination
of cellular viability' Proliferative activity of ovarian carcinoma cells was assessed by using a tetrazolium formazane dye assay (XTT test). Following incubation with neopterin derivatives, cells were treated with 300 μΜ XTT (2,3 bis-(2-methoxy-4-nitro-5-sulfophenyl )-5 [(pheny 1-amino)carbonyl]-2H-tetrazolium hydroxide) and 5 μΜ phenazine methosulfate (PMS) for 4 h at room temperature. XTT is processed into a soluble formazane dye by mitochondrial dehydrogenases using PMS as an electron transfer mediator. The intensity of the dye formation was measured in a microplate reader (Tecan Sunrise, Tecan GmbH, Crailsheim, Germany) at a wavelength of 436 nm. Since mitochondrial enzymes exhibit higher activities in proliferating cells, this assay is convenient for the measurements of cell viability as well as proliferation efficiency. Results of absorption measurements arc given in percent of unstimulated controls.
Reagents DMEM with and without phenol red, fetal calf serum, L-glutamine, and penicillin-streptomycin were purchased from PAA Laboratories, Coelbe, Germany. Neopterin and 7,8-dihydroneopterin were from Schircks Lab., Jona, Switzerland. All other chemicals were from Sigma Chemicals, Deisenhofen, Germany.
Statistical evaluation Results are expressed as mean values ± standard error of the mean (SEM). To test for significance of differences between the mean value of a control vs. the mean value of treated cells, the Student's t-test was used. P-values < 0.05 were considered to be significant. Statistical analyses were performed using the GraphPad Prism 4.0 ® (GraphPad Software, San Diego, USA) software. Figure 1 summarizes the results of the XT Γ assay absorption measurements performed with 2774 cells. With respect to unstimulated controls (100%), no change in cellular viability could be observed after addition of neopterin at 100 μΜ and 1000 μΜ as well as following incubation of 2774 with DHN at concentrations of 100 μΜ and 500 μΜ. The highest concentration of DHN (1000 μΜ) resulted in an increase of mitochondrial dehydrogenase activity ( 166 ± 11.8 %, ρ <0.001 as compared to controls). The stimulating effect of DHN on cellular viability was still present when 2774 were incubated simultaneously with DHN and neopterin at 1000 μΜ, respectively (163 ± 37.6%, ρ <0.05 as compared to controls).
Results
In HOC-7 cells, neither 100 μΜ nor 1000 μΜ of neopterin did affect formazane dye formation as compared to unstimulated controls (Figure 2) . DHN incubations resulted in an increase in mitochondrial enzyme activities. While absorption rates following UC 1 Ν100 Ν1000 DHN100 DHN500 DHN1 000 C100 C1000 Figure 2 . Mitochondrial dehydrogenase activity determined by absorption rate measurements following ^4h-mcubations of HOC-7 cells with: 100 μΜ neopterin (N100), 100 μΜ neopterin (N1000), 100 μΜ 7 8-dihydroneoptenn (DHNIOO), 500 μΜ 7,8-dihydroneopterin (DHN500), 1000 μΜ 7,8-dihydroneopterin (DHNIOOO) as well as combinations (black bars) of 100 μΜ neopterin and 100 μΜ 7,8-dihydroneopterin (CI00) or 1000 μΜ neopterin and 1000 μΜ 7,8-dihydroneopterin (CI000). Results are expressed as percent relative to unstimulated controls (UC, white bar). Data are given as means ± SEM, n=12. * Ρ <0.05 as compared to UC # Ρ <0 05 as compared to DHN 1000.
100 μΜ DHN did not differ from unstimulated controls, higher concentrations of DHN resulted in significantly augmented absorption values (500 μΜ: 139 ± 3.56%; 1000 μΜ: 197 ± 7.89%, ρ <0.001 as compared Pteridines/Vol. 1 7/No. 4
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τ N100 N1000 DHN100 DHN500 DHN1000 C100 C1000 Figure 3 . Mitochondrial dehydrogenase activity determined by absorption rate measurements following 24h-incubations of OVCAR-3 cells with: 100 μΜ neopterin (N100), 100 μΜ neopterin (N1000), 100 μΜ 7,8-dihydroneopterin (DHN100), 500 μΜ 7,8-dihydroneopterin (DHN500), 1000 μΜ 7,8-dihydroneopterin (DHN1000), as well as combinations (black bars) of 100 μΜ neopterin and 100 μΜ 7,8-dihydroneopterin (C100) or 1000 μΜ neopterin and 1000 μΜ 7,8-dihydroneopterin (CI000). Results are expressed as percent relative to unstimulated controls (UC. white bar). Data are given as means ± SEM. n=12. * Ρ <0.05 as compared to UC.
to controls, respectively). Since there was a stronger stimulation of HOC-7 activity following 1000 μΜ DHN as compared to 500 μΜ (ρ <0.001 ), the effect of DHN on mitochondrial dehydrogenases seems to be dose-dependent. In contrast to the results obtained with 2774, simultaneous addition of neopterin affected the DHN-induced stimulation of cellular activity in HOC-7. In comparison to the single application of 1000 μΜ DHN, absorption values were significantly reduced following co-treatment of cells with DHN and neopterin at concentrations of 1000 μΜ (156 ± 10.6%, ρ <0.001 as compared to 1000 μΜ DHN). Statistical analyses of absorption values in OVCAR-3 cells revealed that neopterin was not able to interfere with mitchondrial dehydrogenase activity at any given concentration (Figure 3) . Although not dosedependent, incubation of OVCAR-3 with DHN resulted in a significant increase in absorption rates when given at concentrations of 500 μΜ (177 ± 16.5%, ρ <0.001 as compared to controls), and 1000 μΜ (194 ± 17%, ρ <0.001 as compared to controls). With respect to coincubation experiments, there was a tendency towards lower absorption values following application of 1000 μΜ DHN together with 1000 μΜ neopterin (136 ± 28.9%) as compared to single treatment of OVCAR-3 with 1000 μΜ DHN. However, these differences were not statistically significant.
Discussion
The main finding of the present study is that 7,8-dihydroneopterin stimulates mitochondrial dehydrogenase activity in three different ovarian carcinoma cell lines. Assuming that mitochondrial dehydrogenase turnover rate is representative for the proliferative status of a cell, these data suggest that DHN exerts growth-promoting effects on ovarian carcinomas. In recent studies we could demonstrate distinct biochemical effects of neopterin on tumor cell biology. In HOC-7 and OVCAR-3, the pteridine compound suppressed cytokine-induced nitric oxide synthesis (7). Since nitric oxide production is associated with apoptosis in these cell lines, neopterin might be regarded as an inhibitor of programmed cell death that preserves ovarian carcinomas susceptible to nitric oxide (6) . In addition, neopterin was shown to induce VEGF and EPO gene expression in OVCAR-3 cells (8) . Both play an important role in endothelial growth and in angiogcnctic processes. Accumulation of neopterin within the tumor environment may therefore promote oxygen and nutrient supply for the progressing tumor tissue. The fact that neopterin did not alter mitochondrial dehydrogenase activity in the present study does not contradict our previous findings. Different neopterin derivatives might be involved in separate stages of cellular changes that lead to malignancy via different The potential role of DHN in physiological and pathophysiological processes has been discussed controversially in the past. DHN was described to inhibit TNF-a-induced apoptosis in U937 cells when applied at concentrations below 300 μΜ (10) . However, in the same experimental setup a proapoptotic effect of DHN was observed when cells were incubated with higher concentrations of DHN. Consistent with the latter findings, increased rates of programmed cell death were attributed to DHN in various other cell lines, e.g. Jurkat T-cells, type Il-like pneumocytes as well as astrocytic, neuronal, and microglial cells (11) (12) (13) (14) (15) . Our own data suggest that DHN triggers a growth-promoting intracellular background in ovarian carcinomas. This might be due to its antioxidative properties which have been described in various studies in the past. Chemiluminescence as well as bactericidal effects of reactive oxygen species were found to be reduced in the presence of DHN (16) (17) (18) . Furthermore, oxidation of linolenic acid and LDL as well as formation of 3-nitro-L-tyrosine were prevented by the addition of DHN (19) (20) (21) . In contrast to these data, DHN has been reported to amplify the effect of hydrogen peroxide and nitrite in Escherichia coli and was suggested to support the formation of hydroxyl radicals in cell-free solutions (22, 23) . Although we cannot completely clarify the discrepancies between these findings and our own, the concentrations of DHN used in the various experiments might at least in part explain the different results. DHN seems to exert proapoptotic as well as prooxidative actions only at high amounts, i.e. above the highest concentration of 1000 μΜ used in our studies, whereas lower doses of DHN exhibit antioxidative effects. This hypothesis is supported by our observations made following simultaneous treatment of cells with both neopterin and DHN at equimolar concentrations, in which neopterin at least in part antagonized the stimulating effects of DHN on mitochondrial activity in HOC-7 and OVCAR-3. Since neopterin is regarded to shift the cellular redox state towards a prooxidative situation, one would expect it to interfere with an antioxidant mediator like DHN. A potential flaw of the present experimental setup is the use of very high concentrations of neopterin and DHN. During activation of the cellular immune system, peak values of circulating neotperin and DHN were reported to vary between 100-500 nM. However, the serum pteridine concentrations may not reflect their tissue levels, where an accumulation of activated macrophages may lead to amounts of neopterin and DHN comparable to those used in our in vitro-studies. Thus, local inflammatory reactions within the tumor environment will result in concentrations of neopterin and DHN high enough to affect cellular metabolism. In summary, our new data provide further evidence of distinct biochemical effects of neopterin derivatives in ovarian carcinoma cells. With the effects observed in the present study, both neopterin and 7,8-dihydroneopterin may be involved in separate stages of cellular changes that lead to malignancy or promote tumor progression.
